289 related articles for article (PubMed ID: 24119960)
1. [Choroidal thickness after half-dose verteporfin photodynamic therapy in chronic central serous chorioretinopathy].
Zeng J; Yan YY; Ding XY; Liu R; Li JQ
Zhonghua Yan Ke Za Zhi; 2013 Jun; 49(6):490-4. PubMed ID: 24119960
[TBL] [Abstract][Full Text] [Related]
2. Subfoveal choroidal thickness after treatment of central serous chorioretinopathy.
Maruko I; Iida T; Sugano Y; Ojima A; Ogasawara M; Spaide RF
Ophthalmology; 2010 Sep; 117(9):1792-9. PubMed ID: 20472289
[TBL] [Abstract][Full Text] [Related]
3. Clinical research on one-third dose verteporfin photodynamic therapy in the treatment of chronic central serous chorioretinopathy.
Hua L; Lin B; Hong J; Min HB; Han WL; Zhou TY; Zhang ZQ
Eur Rev Med Pharmacol Sci; 2018 Jan; 22(2):278-284. PubMed ID: 29424884
[TBL] [Abstract][Full Text] [Related]
4. COMPARISON OF PHOTODYNAMIC THERAPY USING HALF-DOSE OF VERTEPORFIN OR HALF-FLUENCE OF LASER LIGHT FOR THE TREATMENT OF CHRONIC CENTRAL SEROUS CHORIORETINOPATHY.
Cheng CK; Chang CK; Peng CH
Retina; 2017 Feb; 37(2):325-333. PubMed ID: 27429374
[TBL] [Abstract][Full Text] [Related]
5. Choroidal thickness following extrafoveal photodynamic treatment with verteporfin in patients with central serous chorioretinopathy.
Pryds A; Larsen M
Acta Ophthalmol; 2012 Dec; 90(8):738-43. PubMed ID: 21586096
[TBL] [Abstract][Full Text] [Related]
6. One-year choroidal thickness results after photodynamic therapy for central serous chorioretinopathy.
Maruko I; Iida T; Sugano Y; Furuta M; Sekiryu T
Retina; 2011 Oct; 31(9):1921-7. PubMed ID: 21878850
[TBL] [Abstract][Full Text] [Related]
7. Half-fluence photodynamic therapy in chronic central serous chorioretinopathy.
Smretschnig E; Ansari-Shahrezaei S; Hagen S; Glittenberg C; Krebs I; Binder S
Retina; 2013 Feb; 33(2):316-23. PubMed ID: 23314238
[TBL] [Abstract][Full Text] [Related]
8. Assessment of choroidal topographic changes by swept source optical coherence tomography after photodynamic therapy for central serous chorioretinopathy.
Razavi S; Souied EH; Cavallero E; Weber M; Querques G
Am J Ophthalmol; 2014 Apr; 157(4):852-60. PubMed ID: 24412124
[TBL] [Abstract][Full Text] [Related]
9. Association between the efficacy of half-dose photodynamic therapy with indocyanine green angiography and optical coherence tomography findings in the treatment of central serous chorioretinopathy.
Nicolò M; Zoli D; Musolino M; Traverso CE
Am J Ophthalmol; 2012 Mar; 153(3):474-480.e1. PubMed ID: 22019224
[TBL] [Abstract][Full Text] [Related]
10. Multimodal Imaging and Choroidal Volumetric Changes After Half-fluence PDT in Central Serous Chorioretinopathy.
Munk MR; Shah R; Pappas F; Baddar D; Wong B; Jampol LM; Fawzi AA
Curr Eye Res; 2016; 41(1):97-106. PubMed ID: 25612245
[TBL] [Abstract][Full Text] [Related]
11. One-year outcomes with half-dose verteporfin photodynamic therapy for chronic central serous chorioretinopathy.
Fujita K; Imamura Y; Shinoda K; Matsumoto CS; Mizutani Y; Hashizume K; Mizota A; Yuzawa M
Ophthalmology; 2015 Mar; 122(3):555-61. PubMed ID: 25444637
[TBL] [Abstract][Full Text] [Related]
12. Effect of Photodynamic Therapy on Optical Coherence Tomography Angiography in Eyes with Chronic Central Serous Chorioretinopathy.
Xu Y; Su Y; Li L; Qi H; Zheng H; Chen C
Ophthalmologica; 2017; 237(3):167-172. PubMed ID: 28171871
[TBL] [Abstract][Full Text] [Related]
13. Detection of morphologic alterations by spectral-domain optical coherence tomography before and after half-dose verteporfin photodynamic therapy in chronic central serous chorioretinopathy.
Shinojima A; Kawamura A; Mori R; Fujita K; Yuzawa M
Retina; 2011 Oct; 31(9):1912-20. PubMed ID: 21952105
[TBL] [Abstract][Full Text] [Related]
14. [Observation on long-term efficacy of half-dose photodynamic therapy with chronic central serous chorioretinopathy using optical coherence tomography].
Liu Y; Li L; Xu G; Wang W
Zhonghua Yan Ke Za Zhi; 2016 May; 52(5):328-34. PubMed ID: 27220704
[TBL] [Abstract][Full Text] [Related]
15. CHOROIDAL THICKNESS AFTER FULL-FLUENCE AND HALF-FLUENCE PHOTODYNAMIC THERAPY IN CHRONIC CENTRAL SEROUS CHORIORETINOPATHY.
Oh BL; Yu HG
Retina; 2015 Aug; 35(8):1555-60. PubMed ID: 25932547
[TBL] [Abstract][Full Text] [Related]
16. Comparison of Focal and Conventional Verteporfin Photodynamic Therapy for Chronic Central Serous Chorioretinopathy.
Noh SR; Kang MS; Kim K; Kim ES; Yu SY
Korean J Ophthalmol; 2019 Dec; 33(6):506-513. PubMed ID: 31833247
[TBL] [Abstract][Full Text] [Related]
17. Early choriocapillaris changes after half-fluence photodynamic therapy in chronic central serous chorioretinopathy evaluated by optical coherence tomography angiography: Preliminary results.
Demircan A; Yesilkaya C; Alkin Z
Photodiagnosis Photodyn Ther; 2018 Mar; 21():375-378. PubMed ID: 29409857
[TBL] [Abstract][Full Text] [Related]
18. Safety enhanced photodynamic therapy with half dose verteporfin for chronic central serous chorioretinopathy: a short term pilot study.
Lai TY; Chan WM; Li H; Lai RY; Liu DT; Lam DS
Br J Ophthalmol; 2006 Jul; 90(7):869-74. PubMed ID: 16597666
[TBL] [Abstract][Full Text] [Related]
19. Half-dose photodynamic therapy followed by diode micropulse laser therapy as treatment for chronic central serous chorioretinopathy: evaluation of a prospective treatment protocol.
Breukink MB; Mohr JK; Ossewaarde-van Norel A; den Hollander AI; Keunen JE; Hoyng CB; Boon CJ
Acta Ophthalmol; 2016 Mar; 94(2):187-97. PubMed ID: 26670630
[TBL] [Abstract][Full Text] [Related]
20. Reduced-fluence photodynamic therapy for subfoveal serous pigment epithelial detachment with choroidal vascular hyperpermeability.
Goto S; Gomi F; Ueno C; Nishida K
Am J Ophthalmol; 2012 Nov; 154(5):865-871.e1. PubMed ID: 22840480
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
